立方製藥(003020.SZ):部分董監高及股東擬減持公司股份
格隆匯6月5日丨立方製藥(003020.SZ)公佈,持有公司股份1,284,660股(佔公司總股本比例0.67%)的公司董事、副總經理王清女士計劃減持公司股份合計不超過321,165股(佔公司總股本比例0.17%)。
持有公司股份573,700股(佔公司總股本比例0.30%)的監事會主席汪琴女士計劃減持公司股份不超過143,425股(佔公司總股本比例0.07%)。
持有公司股份571,459股(佔公司總股本比例0.30%)的副總經理戴天鶴先生計劃減持公司股份不超過142,864股(佔公司總股本比例0.07%)。
持有公司股份416,520股(佔公司總股本比例0.22%)的副總經理鄭勇先生計劃減持公司股份不超過104,130股(佔公司總股本比例0.05%)。
上述董事、監事、高級管理人員減持計劃期間:公吿披露之日起15個交易日後的3個月內(即2025年6月30日至2025年9月29日)以集中競價或大宗交易方式進行。
持有公司股份6,444,703股(佔公司總股本比例3.37%)的股東高美華女士計劃自公吿披露之日起3個交易日後的3個月內(即2025年6月12日至2025年9月11日)以集中競價方式或大宗交易方式減持公司股份不超過300,000股(佔公司總股本比例0.16%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.